
    
      This Phase 2, double-blind, randomized, multicenter, parallel, controlled study is conducted
      to evaluate safety, tolerability, pharmacokinetics and efficacy of TNP-2092, and vancomycin
      in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens. The
      duration of the treatment period is a minimum of 7 days and a maximum of 14 days.
    
  